Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The TRIB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow developments across its infectious disease, diabetes, oncology and maternal health portfolios.
News items for Trinity Biotech commonly highlight regulatory milestones and product launches. Recent announcements include large orders for its TrinScreen HIV rapid screening test, WHO and in-country regulatory approvals enabling offshored and outsourced manufacturing of TrinScreen HIV and Uni-Gold HIV, and expanded rollout of a high-capacity HbA1c column system for the FDA-cleared Premier Hb9210 analyzer. These updates provide insight into how the company is executing its transformation plan and adjusting its manufacturing footprint.
Investors and observers can also use the TRIB news page to track progress in newer areas such as continuous glucose monitoring, where the company has reported breakthrough clinical trial results for a redesigned CGM sensor and references its CGM+ solution, as well as oncology and maternal health initiatives, including development of the EpiCapture prostate cancer test and the PreClara Ratio preeclampsia biomarker service. Capital structure and governance developments, such as credit agreement amendments with Perceptive Advisors, Nasdaq listing compliance updates, and annual general meeting outcomes, are also disclosed through news and associated SEC filings.
By reviewing the Trinity Biotech news stream, users can see how product approvals, manufacturing changes, financing arrangements and clinical data releases intersect with the company’s stated strategy in diagnostics and diabetes management. This page can be revisited to follow new regulatory clearances, commercial orders, pipeline updates and corporate actions as they are reported by the company.
The global pneumonia testing market is anticipated to grow by USD 709 million from 2022 to 2027, with a CAGR of 5.3%.
Key drivers include rising pneumonia prevalence and mortality concerns, spurring demand for timely diagnosis. North America is expected to contribute 32% to market growth, primarily due to the presence of pharmaceutical companies focused on drug development.
However, challenges such as a lack of trained professionals in rural areas may hinder growth. The market is fragmented, with over 15 major vendors, including Abbott Laboratories, Pfizer, and Thermo Fisher Scientific.
The global clostridium diagnostics market is projected to expand by USD 2,148.4 million from 2022 to 2027, with a CAGR of 13.69%. This growth is largely driven by the surge in Clostridium difficile infection (CDI), particularly among the elderly population, where annual incidents in the US reach approximately 200,000. North America is expected to contribute 38% to this growth, propelled by antibiotic use and a growing aging demographic. Key trends include the development of new vaccines and advancements in immunoassays. However, challenges persist, including resource scarcity and lack of awareness in developing regions, hindering widespread diagnosis and treatment.
Trinity Biotech (TRIB) reported its fiscal year and Q4 2022 results, revealing total revenues of $74.8 million, down 19.6% from $93.0 million in 2021, with Q4 revenues at $18.0 million. Excluding COVID-related products, revenues were $71.5 million, a 1.0% decline year-over-year. The company saw a 27% growth in its diabetes product line. Despite a 14% decline in the HIV business due to non-recurring orders in 2021, the overall performance remains strong thanks to significant growth in high-margin consumables. However, operational losses reached $7.8 million in Q4, resulting in a basic loss per ADS of $0.27.
The global Diabetes Diagnostics market, valued at $30.8 billion in 2022, is anticipated to grow to $59.4 billion by 2030, representing a CAGR of 8.6%. Segment analysis reveals that Test Strips will reach $14.7 billion with a CAGR of 8.7%. The U.S. market is projected at $11.7 billion in 2022, and China is forecasted to grow at 10.1% CAGR, reaching $7.6 billion by 2030. Despite ongoing economic challenges, the diabetes diagnostics sector shows resilience, driven by increasing healthcare expenditure and the rising incidence of diabetes globally.
The North America point-of-care diagnostics market is projected to reach USD 28.46 billion by 2030, growing at a CAGR of 6.2% due to the increasing geriatric population and the demand for immediate testing results. Notable funding from various sources, including the U.S. Department of Defense and the Bill & Melinda Gates Foundation, is expected to accelerate advancements in point-of-care technologies. The report indicates that products for infectious diseases currently dominate the market, driven by COVID-19 testing. Clinics are the leading end-use segment, reflecting consumer preference for convenience.
Trinity Biotech (Nasdaq: TRIB) announced that the Kenyan Ministry of Health has adopted its TrinScreen HIV as the screening test under WHO guidelines. This program is among the largest in Africa, with 7-9 million tests annually. The new algorithm deployment is expected to commence in Q2 2023. The African screening market for HIV is valued at approximately USD 150 million. The Kenyan adoption marks a significant endorsement of TrinScreen HIV’s quality and positions Trinity Biotech for expanded opportunities in other African nations. The company is ramping up manufacturing capacity in Ireland to meet anticipated demand.
The global market for Adult Hemoglobinopathy Testing is projected to grow from US$368.6 Million in 2022 to US$513.7 Million by 2030, with a CAGR of 4.2%. The U.S. market alone is estimated at US$98.2 Million, while China is expected to grow at a remarkable 6.6% CAGR, reaching US$110.4 Million by 2030. Key players include Trinity Biotech, PerkinElmer, and Thermo Fisher Scientific. Notable trends impacting growth involve post-pandemic recovery and competitive dynamics across various geographic regions.
Trinity Biotech will report its financial results for the fourth quarter and fiscal year 2022 on March 23, 2023. A conference call is scheduled for 10:00 am ET (2:00 pm GMT) to discuss these results. Interested participants can join via US Toll Free at 1-844-861-5499 or access a webcast online. Replays will be available until March 30, 2023, with a specific dial-in code provided for conference call replay. The company continues to develop diagnostic products for the clinical and point-of-care markets, emphasizing its commitment to addressing infectious diseases and other health parameters.
The transport media market was valued at $13 billion in 2022 and is projected to decline to $12.59 billion by 2028, indicating a CAGR of -0.73%.
Factors contributing to this decline include the ongoing impacts of the COVID-19 pandemic, which initially boosted demand for transport media solutions such as viral transport medium (VTM). However, the market is experiencing adjustments as pandemic-related demand stabilizes.
The report provides insights into market dynamics, segmentation, and regional performance, highlighting North America as a market leader due to high diagnostic testing rates.
Technavio projects the infectious disease market to grow by USD 104.81 billion from 2022 to 2027, with a CAGR of 12.49%. Growth is attributed to the rising prevalence of infectious diseases due to lifestyle changes, climate variability, and drug-resistant pathogens. The market is expected to see significant contributions from the drugs segment, driven by increased awareness and funding for R&D. Major players include Trinity Biotech, Bio Rad Laboratories, Danaher Corp., and Hoffmann La Roche. North America is anticipated to dominate with a share of 42%.